By VETTAPHARMA reporter – Derek Roche: MannKind reported that the U.S. Food and Drug Administration (FDA) approved Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 years and older living with type 1 or type 2 diabetes, making it the first and only inhaled mealtime insulin available for pediatric patients in the United States. The approval expands the product beyond its existing adult indication and introduces a needle-free mealtime insulin option for younger patients requiring insulin therapy.
MannKind reported that it will host a conference call and webcast to discuss the recent FDA approval of Afrezza for children and adolescents aged 6 years and older with diabetes. The event is expected to provide investors and stakeholders with additional details regarding the approval, its implications for the company, and the expansion of Afrezza into the pediatric market.
The regulatory decision allows Afrezza to be used in children and adolescents aged 6 years and older and follows the FDA’s review of MannKind’s supplemental application seeking pediatric label expansion. The company said management would host a conference call to discuss the approval and its implications.
Afrezza is a rapid-acting inhaled insulin administered at the beginning of meals through a portable inhaler. The therapy is designed to provide a fast onset and short duration of action that more closely mirrors the body’s natural insulin response to meals. The product was previously approved for adults with diabetes before receiving the expanded pediatric indication.
The pediatric approval represents a significant regulatory milestone for MannKind’s diabetes franchise, extending access to a treatment option designed to reduce reliance on mealtime insulin injections. The expanded label adds a new treatment alternative for children and adolescents requiring insulin therapy as part of daily diabetes management.
For patients and caregivers, the approval introduces an additional mealtime insulin option that may offer greater flexibility during school, sports, meals, and other daily activities. The expanded indication broadens treatment choices for pediatric patients living with diabetes who require insulin therapy.
Commercially, the approval expands Afrezza’s addressable patient population and strengthens MannKind’s position in diabetes care. The pediatric label expansion extends the reach of the company’s inhaled insulin platform into a new patient segment and supports its broader diabetes portfolio strategy.
Quick FAQs
1. What is Afrezza?
Afrezza is a rapid-acting inhaled mealtime insulin used to improve glycemic control in people with diabetes.
2. What happened?
The FDA approved Afrezza for use in children and adolescents aged 6 years and older with type 1 or type 2 diabetes.
3. What is the regulatory milestone?
The approval expands Afrezza’s label to include pediatric patients, making it available to children and adolescents for the first time.
4. What disease condition does Afrezza treat?
Afrezza is used as a mealtime insulin therapy for people with type 1 or type 2 diabetes.
5. What is the most important outcome from this approval?
Afrezza became the first and only inhaled mealtime insulin approved for children and adolescents aged 6 years and older living with diabetes.
6. Why is this important?
The approval expands access to a needle-free mealtime insulin option and broadens treatment choices for pediatric patients requiring insulin therapy.
